Necrostatin: A Potentially Novel Cardioprotective Agent?
Top Cited Papers
- 31 July 2007
- journal article
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 21 (4) , 227-233
- https://doi.org/10.1007/s10557-007-6035-1
Abstract
Necrostatin-1 (Nec-1), a small tryptophan-based molecule, was recently reported to protect the cerebral cortex against ischemia-reperfusion (I/R) injury. We investigated the actions of Nec-1 and its so-called inactive analog, Nec-1i, in the setting of myocardial I/R injury. The actions of Nec-1 and Nec-1i were examined in cultured C2C12 and H9c2 myocytes, cardiomyocytes isolated from male Sprague–Dawley rats, Langendorff isolated perfused C57Bl/6J mouse hearts and an in vivo open-chest C57Bl/6J mouse heart model. Nec-1 at 30 μM and 100 μM (but not 100 μM Nec-1i) reduced peroxide-induced cell death in C2C12 cells from 51.2 ± 1.1% (control) to 26.3 ± 2.9% (p < 0.01 vs control) and 17.8 ± 0.9% (p < 0.001), respectively. With H9c2 cells cell death was also reduced from 73.0 ± 0.4% (control) to 56.7 ± 0% (30 μM Nec-1, p < 0.05) and 45.4 ± 3.3% (100 μM Nec-1, p < 0.01). In the isolated perfused heart Nec-1 (30 μM) reduced infarct size (calculated as a percentage of the risk area) from 48.0 ± 2.0% (control) to 32.1 ± 5.4% (p < 0.05). Nec-1i (30 μM) also reduced infarct size (32.9 ± 5.1%, p < 0.05). In anesthetized C57Bl/6J mice Nec-1 (1.65 mg/kg), given intraperitoneally to coincide with reperfusion following left anterior descending artery ligation (30 min), also reduced infarct size from 45.3 ± 5.1% (control) to 26.6 ± 4.0% (p < 0.05), whilst Nec-1i (1.74 mg/kg) was ineffective (37.8 ± 6.0%). Stimulus-induced opening of the mitochondrial permeability transition pore (MPTP) in rat cardiomyocytes, as reflected by the time until mitochondrial depolarisation, was unaffected by Nec-1 or Nec-1i at 30 μM but increased at 100 μM i.e. 91% (p < 0.05 vs control) and 152% (p < 0.001) for Nec-1 and Nec-1i, respectively. This is the first study to demonstrate that necrostatins inhibit myocardial cell death and reduce infarct size, possibly via a mechanism independent of the MPTP.Keywords
This publication has 21 references indexed in Scilit:
- Pioglitazone Mimics Preconditioning in the Isolated Perfused Rat HeartJournal of Cardiovascular Pharmacology, 2005
- Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivoBasic Research in Cardiology, 2005
- Atorvastatin and Myocardial Reperfusion InjuryJournal of Cardiovascular Pharmacology, 2005
- Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion InjuryDiabetes, 2005
- Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioningCardiovascular Research, 2004
- New directions for protecting the heart against ischaemia–reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathwayCardiovascular Research, 2004
- Mitochondrial permeability transition pore opening during myocardial reperfusion—a target for cardioprotectionCardiovascular Research, 2004
- Role of bradykinin in preconditioning and protection of the ischaemic myocardiumBritish Journal of Pharmacology, 2002
- Myocardial Protection by Insulin at Reperfusion Requires Early Administration and Is Mediated via Akt and p70s6 Kinase Cell-Survival SignalingCirculation Research, 2001
- Cardiomyocyte apoptosis in acute and chronic conditionsBasic Research in Cardiology, 1998